CN1997356A - 持续释放制剂 - Google Patents

持续释放制剂 Download PDF

Info

Publication number
CN1997356A
CN1997356A CNA2005800124592A CN200580012459A CN1997356A CN 1997356 A CN1997356 A CN 1997356A CN A2005800124592 A CNA2005800124592 A CN A2005800124592A CN 200580012459 A CN200580012459 A CN 200580012459A CN 1997356 A CN1997356 A CN 1997356A
Authority
CN
China
Prior art keywords
peptide
cpg
pgg
gallate
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800124592A
Other languages
English (en)
Chinese (zh)
Inventor
M·S·戈登伯格
J·H·古
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CN201410023256.4A priority Critical patent/CN103920162B/zh
Publication of CN1997356A publication Critical patent/CN1997356A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2005800124592A 2004-04-23 2005-04-25 持续释放制剂 Pending CN1997356A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410023256.4A CN103920162B (zh) 2004-04-23 2005-04-25 持续释放制剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56524704P 2004-04-23 2004-04-23
US60/565,247 2004-04-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410023256.4A Division CN103920162B (zh) 2004-04-23 2005-04-25 持续释放制剂

Publications (1)

Publication Number Publication Date
CN1997356A true CN1997356A (zh) 2007-07-11

Family

ID=34967842

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2005800124592A Pending CN1997356A (zh) 2004-04-23 2005-04-25 持续释放制剂
CN201410023256.4A Expired - Fee Related CN103920162B (zh) 2004-04-23 2005-04-25 持续释放制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410023256.4A Expired - Fee Related CN103920162B (zh) 2004-04-23 2005-04-25 持续释放制剂

Country Status (15)

Country Link
US (2) US7323169B2 (2)
EP (1) EP1750683B1 (2)
JP (3) JP5036533B2 (2)
KR (1) KR101201638B1 (2)
CN (2) CN1997356A (2)
AU (1) AU2005237542B2 (2)
CA (1) CA2563185C (2)
DK (1) DK1750683T3 (2)
ES (1) ES2400687T3 (2)
IL (1) IL178596A (2)
PL (1) PL1750683T3 (2)
PT (1) PT1750683E (2)
SI (1) SI1750683T1 (2)
WO (1) WO2005105057A1 (2)
ZA (1) ZA200609401B (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1750683B1 (en) * 2004-04-23 2013-01-09 Amgen Inc. Sustained release formulations
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US7252834B2 (en) 2005-04-25 2007-08-07 Clemson University Research Foundation (Curf) Elastin stabilization of connective tissue
CN101258163B (zh) * 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
CA2642632A1 (en) * 2006-02-15 2007-10-18 Gammacan Ltd. Immunoglobulins from vitiligo plasma for melanoma therapy
US20090173876A1 (en) * 2006-07-21 2009-07-09 Amgen Inc. Method of detecting and/or measuring hepcidin in a sample
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
EP2235058A2 (en) 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
US20090214654A1 (en) * 2008-02-21 2009-08-27 Isenburg Jason C Treatment of aneurysm with application of connective tissue stabilization agent in combination with a delivery vehicle
US20100016833A1 (en) * 2008-07-15 2010-01-21 Ogle Matthew F Devices for the Treatment of Vascular Aneurysm
US20100119605A1 (en) * 2008-11-12 2010-05-13 Isenburg Jason C Compositions for tissue stabilization
US8444624B2 (en) * 2009-10-19 2013-05-21 Vatrix Medical, Inc. Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections
US8911468B2 (en) 2011-01-31 2014-12-16 Vatrix Medical, Inc. Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection
PH12013501865A1 (en) 2011-03-16 2014-01-06 Amgen Inc Potent and selective inhibitors of nav1.3 and nav1.7
EP2709711B8 (en) 2011-05-18 2017-03-22 Vatrix Medical, Inc. Coated balloons for blood vessel stabilization
HK1203384A1 (en) * 2011-12-19 2015-12-11 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
AU2014212014A1 (en) 2013-02-01 2015-08-27 Amgen Inc. Administration of an anti-activin-A compound to a subject
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
WO2018226383A1 (en) * 2017-06-07 2018-12-13 Egy-Nano Pharma, Lp Oral prolonged drug delivery platforms
WO2020027882A1 (en) 2018-08-03 2020-02-06 Nectero Medical, Inc. Purified pentagalloyl glucose and devices for delivery
WO2020227437A1 (en) 2019-05-06 2020-11-12 Axial Biotherapeutics, Inc. Sustained release solid dosage forms for modulating the colonic microbiome
CN119326891B (zh) * 2024-10-31 2025-07-01 中国人民解放军空军军医大学 Ei24激动剂以及在制备抑制食管鳞癌增殖的制剂的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
GB929406A (en) 1958-12-22 1963-06-19 Upjohn Co A process for the production of encapsulated material
CH498653A (fr) 1968-03-29 1970-11-15 Kobayashi Takehiko Procédé d'encapsulation de matières hydrophobes
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
JP2744572B2 (ja) * 1993-02-17 1998-04-28 鐘紡株式会社 ポリフェノール化合物含有皮膚外用剤組成物の変色防止方法
JPH06345668A (ja) * 1993-06-07 1994-12-20 Shibayagi:Kk 感染防御組成物およびその用途
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
WO1997007788A2 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
WO1998010649A1 (en) 1996-09-13 1998-03-19 University Technology Corporation Biocompatible cationic detergents and uses therefor
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6531154B1 (en) * 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
AU8578498A (en) * 1997-07-23 1999-02-16 Perio Products Ltd. Tannic acid-polymer compositions for controlled release of pharmaceutical agents, particularly in the oral cavity
US6180666B1 (en) 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US5962522A (en) * 1997-09-05 1999-10-05 Avmax, Inc. Propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
US6613358B2 (en) * 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
CA2325983C (en) * 1998-04-20 2009-02-17 Genzyme Corporation Drug delivery of proteins from polymeric blends
JP2000080027A (ja) * 1998-09-02 2000-03-21 Taiyo Kagaku Co Ltd 徐放性製剤
US6428818B1 (en) * 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
WO2001032218A1 (en) 1999-11-01 2001-05-10 University Technology Corporation Compositions and methods for controlled-release delivery and increased potency of pharmaceuticals via hydrophobic ion-pairing
US6713506B2 (en) * 2000-10-11 2004-03-30 University Of South Florida Tea polyphenol esters and analogs thereof for cancer prevention and treatment
US6759064B2 (en) * 2001-02-22 2004-07-06 Purdue Research Foundation Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
JP5013152B2 (ja) * 2001-02-28 2012-08-29 株式会社ビーエムジー 蛋白質複合体形成剤
US20040142048A1 (en) * 2002-02-22 2004-07-22 Morre Dorothy M. Compositions based on proanthocyanadin-catechin synergies for prevention and treatment of cancer
WO2004012522A1 (en) 2002-07-26 2004-02-12 Dsm Ip Assets B.V. Compositions comprising lactoferrin
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7605120B2 (en) * 2003-10-22 2009-10-20 Amgen Inc. Antagonists of the brandykinin B1 receptor
EP1750683B1 (en) * 2004-04-23 2013-01-09 Amgen Inc. Sustained release formulations

Also Published As

Publication number Publication date
US7323169B2 (en) 2008-01-29
WO2005105057A1 (en) 2005-11-10
CA2563185A1 (en) 2005-11-10
US20050271722A1 (en) 2005-12-08
PT1750683E (pt) 2013-01-25
DK1750683T3 (da) 2013-04-15
PL1750683T3 (pl) 2013-05-31
HK1200092A1 (en) 2015-07-31
EP1750683A1 (en) 2007-02-14
EP1750683B1 (en) 2013-01-09
JP2007534698A (ja) 2007-11-29
ZA200609401B (en) 2008-05-28
AU2005237542A1 (en) 2005-11-10
AU2005237542B2 (en) 2009-12-17
IL178596A0 (en) 2007-02-11
JP5829870B2 (ja) 2015-12-09
KR101201638B1 (ko) 2012-11-15
JP2012046520A (ja) 2012-03-08
HK1103023A1 (en) 2007-12-14
KR20070026457A (ko) 2007-03-08
ES2400687T3 (es) 2013-04-11
JP5036533B2 (ja) 2012-09-26
US7732399B2 (en) 2010-06-08
CA2563185C (en) 2010-04-20
US20070292506A1 (en) 2007-12-20
CN103920162A (zh) 2014-07-16
CN103920162B (zh) 2017-07-11
JP2012036194A (ja) 2012-02-23
SI1750683T1 (sl) 2013-04-30
IL178596A (en) 2012-06-28

Similar Documents

Publication Publication Date Title
US7732399B2 (en) Sustained release formulations
JP5657698B2 (ja) 持続型顆粒球コロニー刺激因子結合体の液剤
KR101303388B1 (ko) 지속형 인터페론 알파 결합체의 액상 제제
KR20120007182A (ko) 지속형 인간 성장 호르몬 결합체 액상 제제
TW201141512A (en) Liquid formulations for long-acting erythropoietin conjugate
CN108136276A (zh) 通过使用免疫球蛋白片段的特异性位点进行连接的蛋白质复合物
US20230165964A1 (en) Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
JP2019511497A (ja) エキセナチド類似体の持続放出コンジュゲート
KR102364521B1 (ko) 알부민 및 폴리에틸렌글리콜을 포함하는 하이드로겔 및 그의 제조방법
HK1103023B (en) Sustained release formulations
HK1200092B (en) Sustained release formulations
MXPA06012009A (es) Formulaciones de liberacion prolongada
JP6527697B2 (ja) タンパク質を安定化させたゲル状製剤
CN117731621A (zh) 胰高血糖素样肽-1缓释微球制剂及其制备方法
HK40064590A (en) Extended release conjugates of exenatide analogs
KR20220074813A (ko) 비오틴 모이어티, 지방산 모이어티 또는 이의 조합이 결합된 생리활성 물질 접합체
CN113527505A (zh) 一种多肽和包含该多肽的药物组合物以及它们的应用
NZ786229A (en) Extended release conjugates of exenatide analogs
HK1175721A (en) Liquid formulations for long-acting g-csf conjugate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20070711